Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

Summary

This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement. It is intended to compare the efficacy and safety of ruxolitinib cream 1.5% BID versus vehicle cream, then further evaluate ruxolitinib cream as maintenance during the open label extension period.

Timeline

Start

2021-11-10

Primary completion

2023-08-03

Completion

2023-09-29

Outcome

Missed primary endpoint

paper More patients who applied ruxolitinib cream vs vehicle achieved head/neck EASI-75 at Week 4 (37.0% vs 17.4%; p = 0.091). PMID 40132224 ↗

Publications

• Chiesa Fuxench ZC, Lai Z, Kuo Y, Nawaz H, Cotliar J. Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial. J Dermatolog Treat. 2025 Dec;36(1):2480744. doi: 10.1080/09546634.2025.2480744. Epub 2025 Mar 25.

Drugs

Indications